MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

866.626.6847

Human papillomavirus (HPV) Vaccine

Selected References:

  • American College of Obstetricians and Gynecologists. 2013. ACOG committee opinion no. 558: Integrating immunizations into practice. Obstet Gynecol 121(4):897-903.
  • Angelo MG, et al. 2014. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 23(5):466-79.
  • Baril L, et al. 2015. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine 33(48):6884-91.
  • Bukowinski AT, et al. 2020. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy. Vaccine. 18;38(37):5933-5939.
  • Centers for Disease Control and Prevention. 2016. Guidelines for vaccinating pregnant women. Available at https://www.cdc.gov/vaccines/pubs/preg-guide.htm
  • Chen W, et al. 2019. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine 37(6):889-97.
  • Faber MT, et al 2019. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy. Vaccine 37(2)265-271.
  • Garland SM, et al. 2009. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114(6):1179-1188.
  • Garolla A et. Al. 2013. Sperm viral infection and male infertility: focus on HBV, HCV, HIV, HPV, HSV, HCMV, and AAV. J Reprod Immunol 100(1):20-9.
  • Goss MA, et al. 2015. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 33(29): 3422-3428.
  • Kharbanda EO, et al. 2018. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. Obstet Gynecol 132:34-44.
  • Kharbanda EO, et al. 2021. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open 4(4): e214340.
  • Landazabal CS, et al. 2019. Safety of 9- valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. Vaccine 37:1229-1234.
  • Lawton B, et al. 2018. Association of prior HPV vaccinations with reduced preterm birth: a population based study. Vaccine 36: 134-140.
  • Lipkind HS, et al. 2017. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstet Gynecol; 130(3):599-608.
  • Mammas IN, et al. 2011. Can ‘high-risk’ human papillomaviruses (HPVs) be detected in human breast milk? Acta Paediatr 100(5):705-7.
  • Markowitz LE, et al. 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (RR-2):1-24.
  • Matys K, et al. 2012. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol Jun; 19(6):881-5.
  • McDonnold M, et al. 2014. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol 210(2):138.e1-5.
  • Moreira ED, E et al. 2016. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 138(2):e20154387.
  • Muscianisi F, Foresta C, Garolla A. Role of HPV vaccination for prevention of male infertility. Minerva Endocrinol (Torino). 2022 Mar;47(1):70-76.
  • Panagiotou OA, et al. 2015. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 7; 351:h4358.
  • Segal L, et al. 2011. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 31(1):111-20.
  • Scheller NM, et al. 2017. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med 376:1223-1233.
  • Wacholder S, et al. 2010. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized clinical trials. BMJ 340:C712.
  • Wang A, et al. 2020. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. Hum Vaccin Immunother. 3;16(3):581-589.
  • Wise LD, et al. 2008. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res (B) 83:561-572.
  • Muscianisi F, Foresta C, Garolla A. Role of HPV vaccination for prevention of male infertility. Minerva Endocrinol (Torino). 2022 Mar;47(1):70-76.

 

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.